Development of novel therapeutic strategies
Pancreatic cancer is highly metastatic and often chemo-resistant. We’re taking a multi-prong approach to develop novel therapies to increase the overall survival of our patients. Over 90% of pancreatic patients have genetic abnormalities in a specific gene called KRAS. We’ve developed a way to silence these abnormalities using a novel delivery system called “iExosomes.” We’re also developing targeted therapies that inhibit recurrently abnormal genes and pathways in pancreatic cancer, investigating how to adapt immunotherapy into a treatment option for this disease and developing a liquid biopsy to personalize patient treatment.